Heavier smoking may lead to a relative increase in waist circumference: evidence for a causal relationship from a Mendelian randomisation meta-analysis. The CARTA consortium. by Morris, Richard W et al.
Morris, RW; Taylor, AE; Fluharty, ME; Bjrngaard, JH; svold, BO;
Elvestad Gabrielsen, M; Campbell, A; Marioni, R; Kumari, M; Ko-
rhonen, T; Mnnist, S; Marques-Vidal, P; Kaakinen, M; Cavadino,
A; Postmus, I; Husemoen, LL; Skaaby, T; Ahluwalia, TV; Treur,
JL; Willemsen, G; Dale, C; Wannamethee, SG; Lahti, J; Palotie, A;
Rikknen, K; McConnachie, A; Padmanabhan, S; Wong, A; Dalgrd,
C; Paternoster, L; Ben-Shlomo, Y; Tyrrell, J; Horwood, J; Fergus-
son, DM; Kennedy, MA; Nohr, EA; Christiansen, L; Kyvik, KO;
Kuh, D; Watt, G; Eriksson, JG; Whincup, PH; Vink, JM; Boomsma,
DI; Davey Smith, G; Lawlor, D; Linneberg, A; Ford, I; Jukema,
JW; Power, C; Hyppnen, E; Jarvelin, MR; Preisig, M; Borodulin,
K; Kaprio, J; Kivimaki, M; Smith, BH; Hayward, C; Romundstad,
PR; Srensen, TI; Munaf, MR; Sattar, N (2015) Heavier smoking may
lead to a relative increase in waist circumference: evidence for a
causal relationship from a Mendelian randomisation meta-analysis.
The CARTA consortium. BMJ Open, 5 (8). e008808. ISSN 2044-
6055 DOI: 10.1136/bmjopen-2015-008808
Downloaded from: http://researchonline.lshtm.ac.uk/2274386/
DOI: 10.1136/bmjopen-2015-008808
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
Heavier smoking may lead to a relative
increase in waist circumference:
evidence for a causal relationship from
a Mendelian randomisation
meta-analysis. The CARTA consortium
Richard W Morris,1,2 Amy E Taylor,3,4 Meg E Fluharty,3,4 Johan H Bjørngaard,5,6
Bjørn Olav Åsvold,5,7 Maiken Elvestad Gabrielsen,8 Archie Campbell,9
Riccardo Marioni,9,10,11 Meena Kumari,12 Tellervo Korhonen,13,14,15 Satu Männistö,13
Pedro Marques-Vidal,16 Marika Kaakinen,17,18 Alana Cavadino,19,20 Iris Postmus,21,22
Lise Lotte N Husemoen,23 Tea Skaaby,23 Tarun Veer Singh Ahluwalia,24,25,26
Jorien L Treur,27 Gonneke Willemsen,27 Caroline Dale,28 S Goya Wannamethee,2
Jari Lahti,29,30 Aarno Palotie,31,32,33 Katri Räikkönen,29 Alex McConnachie,34
Sandosh Padmanabhan,35 Andrew Wong,36 Christine Dalgård,37 Lavinia Paternoster,1,3
Yoav Ben-Shlomo,1 Jessica Tyrrell,38,39 John Horwood,40 David M Fergusson,40
Martin A Kennedy,41 Ellen A Nohr,42 Lene Christiansen,43 Kirsten Ohm Kyvik,37
Diana Kuh,36 Graham Watt,44 Johan G Eriksson,15,30,45,46,47 Peter H Whincup,48
Jacqueline M Vink,27 Dorret I Boomsma,27 George Davey Smith,1,3 Debbie Lawlor,1,3
Allan Linneberg,23,49,50 Ian Ford,34 J Wouter Jukema,51,52,53 Chris Power,20
Elina Hyppönen,20,54,55 Marjo-Riitta Jarvelin,17,18,56,57,58 Martin Preisig,59 Katja Borodulin,15
Jaakko Kaprio,13,15,60 Mika Kivimaki,61 Blair H Smith,62 Caroline Hayward,63
Pål R Romundstad,5 Thorkild I A Sørensen,3,24,64 Marcus R Munafò,3,4 Naveed Sattar65
To cite: Morris RW,
Taylor AE, Fluharty ME, et al.
Heavier smoking may lead to
a relative increase in waist
circumference: evidence for a
causal relationship from a
Mendelian randomisation
meta-analysis. The CARTA
consortium. BMJ Open
2015;5:e008808.
doi:10.1136/bmjopen-2015-
008808
▸ Prepublication history and
additional material is
available. To view please visit
the journal (http://dx.doi.org/
10.1136/bmjopen-2015-
008808).
Received 18 May 2015
Revised 14 July 2015
Accepted 21 July 2015
For numbered affiliations see
end of article.
Correspondence to
Professor Richard W Morris;
richard.morris@bristol.ac.uk
ABSTRACT
Objectives: To investigate, using a Mendelian
randomisation approach, whether heavier smoking is
associated with a range of regional adiposity phenotypes,
in particular those related to abdominal adiposity.
Design:Mendelian randomisation meta-analyses using
a genetic variant (rs16969968/rs1051730 in the
CHRNA5-CHRNA3-CHRNB4 gene region) as a proxy for
smoking heaviness, of the associations of smoking
heaviness with a range of adiposity phenotypes.
Participants: 148 731 current, former and never-
smokers of European ancestry aged ≥16 years from 29
studies in the consortium for Causal Analysis Research in
Tobacco and Alcohol (CARTA).
Primary outcome measures:Waist and hip
circumferences, and waist-hip ratio.
Results: The data included up to 66 809 never-smokers,
43 009 former smokers and 38 913 current daily
cigarette smokers. Among current smokers, for each
extra minor allele, the geometric mean was lower for
waist circumference by −0.40% (95% CI −0.57% to
−0.22%), with effects on hip circumference, waist-hip
ratio and body mass index (BMI) being −0.31% (95% CI
−0.42% to −0.19), −0.08% (−0.19% to 0.03%) and
−0.74% (−0.96% to −0.51%), respectively. In contrast,
among never-smokers, these effects were higher by
0.23% (0.09% to 0.36%), 0.17% (0.08% to 0.26%),
0.07% (−0.01% to 0.15%) and 0.35% (0.18% to
0.52%), respectively. When adjusting the three central
adiposity measures for BMI, the effects among current
smokers changed direction and were higher by 0.14%
(0.05% to 0.22%) for waist circumference, 0.02%
(−0.05% to 0.08%) for hip circumference and 0.10%
(0.02% to 0.19%) for waist-hip ratio, for each extra
minor allele.
Conclusions: For a given BMI, a gene variant associated
with increased cigarette consumption was associated
with increased waist circumference. Smoking in an effort
to control weight may lead to accumulation of central
adiposity.
Strengths and limitations of this study
▪ This is a very large Mendelian randomisation
study of the relationship between smoking and
several anthropometric phenotypes relating to
regional adiposity.
▪ Data included never, former and current smokers
from a very wide spectrum of ages among 29
studies.
▪ By using a genetic variant associated with
smoking heaviness as a proxy for smoking heavi-
ness, bias from confounding is minimised and
findings are not affected by reverse causality.
▪ Data for direct measures of fat, such as fat
mass, and the biomarker leptin were available for
only about one fifth of the participants whose
weight, height, waist and hip were measured.
▪ Participants were exclusively of self-reported
European ancestry, and were mostly recruited in
European countries.
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INTRODUCTION
Tobacco is the single most important cause of preventable
death globally: one in two young people taking up lifelong
cigarette smoking will die of causes related to it.1
Enormous efforts have gone into developing interventions
for smoking cessation. Spontaneous cessation rates are low
due to the high proportion of smokers who are dependent
on nicotine, and effective treatments are still not widely
available. One barrier to smoking cessation is the fear of
weight gain. In a study of almost 2000 smokers in the USA,
recruited into a trial of bupropion and/or nicotine inha-
lers to promote cessation, 50% of female and 26% of male
smokers reported that gaining weight discouraged them
from trying to quit,2 while among adults in Finland, daily
smokers were found to report more weight concerns than
former smokers or occasional smokers.3
A genetic variant in the chromosome 15 CHRNA5-
CHRNA3-CHRNB4 gene region (rs16969968) codes for a
functional amino acid change D398N in the nicotinic
receptor α5 subunit. The SNP rs16969968, which is in
perfect linkage disequilibrium with SNP rs1051730 in
European populations, is associated with smoking quan-
tity among smokers.4 The minor allele of this variant is
associated with an average increase in smoking amount
of one cigarette per day in smokers and increases in coti-
nine (a metabolite of nicotine) levels.5 6 It has also been
found that the variant was associated with a lower mean
body mass index (BMI),7–9 thus adding evidence that
heavier smoking leads to lower BMI. The latter study
also noted lower waist and hip circumferences among
smokers with the variant.8 However, prior observational
evidence suggests that waist circumference and waist-hip
ratio may be higher in smokers than in non-smokers
after adjusting for BMI.10 It has also been observed that
smoking in adolescence predicts abdominal obesity in
adulthood.11 Moreover, heavy smokers exhibit greater
central adiposity than light smokers, based on an ana-
lysis of middle-aged smokers of European ancestry.12
These studies suggest that smoking leads to a central fat
accumulation at the expense of peripheral fat loss, par-
ticularly in women.13 In addition, there are also sugges-
tions that smoking may lead to loss of muscle mass as
indicated by lower hip circumferences in smokers. This
is of high public health relevance in view of the report-
edly greater impact of increased central adiposity both
on mortality14 15 and on the development of diabetes,
especially among women,16 17 and since smoking is asso-
ciated with an increased risk of type 2 diabetes.18
We previously used Mendelian randomisation methods
to investigate the effect of smoking quantity on BMI.7 9
This method exploits Mendel’s laws concerning the
random assortment of alleles at the time of gamete forma-
tion so that individuals are allocated at random to having
0, 1 or 2 alleles in the rs1051730/rs16969968 genotype.
The effect of this genotype on smoking quantity among
smokers has been demonstrated,6 and thus the inverse
relationship between allele count and BMI is not subject
to effects of confounding and reverse causality. Using a
substantial pool of studies in the consortium for Causal
Analysis Research in Tobacco and Alcohol (CARTA), we
have extended our use of Mendelian randomisation
methods to examine the effect of smoking quantity on a
range of adiposity phenotypes. We test the hypotheses that
(1) phenotypes representing central adiposity are affected
by smoking quantity differentially from other phenotypes,
and (2) these effects are more marked among women
than among men.
METHODS
Study populations
We used data on individuals (≥16 years) of self-reported
European ancestry from 29 studies from the CARTA con-
sortium (http://www.bris.ac.uk/expsych/research/
brain/targ/research/collaborations/carta/): the 1958
Birth Cohort (1958BC), the Avon Longitudinal Study of
Parents and Children (ALSPAC, including both mothers
and children), the British Regional Heart Study
(BRHS), the British Women’s Heart and Health Study
(BWHHS), the Caerphilly Prospective Study (CaPS), the
Christchurch Health and Development Study (CHDS),
CoLaus, the Danish Monica study (Dan-MONICA), the
Exeter Family Study of Child Health (EFSOCH),
the English Longitudinal Study of Ageing (ELSA), the
National FINRISK studies, GEMINAKAR, GS:SFHS
(Generation Scotland: Scottish Family Health Study),
the Genomics of Overweight Young Adults (GOYA)
females, GOYA males, the Helsinki Birth Cohort Study
(HBCS), Health2006, Health2008, the Nord-Trøndelag
Health Study (HUNT), Inter99, MIDSPAN, the
Northern Finland Birth Cohorts (NFBC 1966 and NFBC
1986), the National Health and Nutrition Examination
Survey (NHANES), the MRC National Survey of Health
& Development (NSHD), the Netherlands Twin Register
(NTR), the PROspective Study of Pravastatin in the
Elderly at Risk (PROSPER) and Whitehall II. All studies
received ethics approval from the local research ethics
committees. Further details of these studies are provided
in online supplementary material.
Genotype
Within each study, individuals were genotyped for one of
two single nucleotide polymorphisms (SNPs) in the
CHRNA5-A3-B4 nicotinic receptor subunit gene cluster,
either rs16969968 or rs1051730. These SNPs are in perfect
linkage disequilibrium with each other in Europeans
(R2=1.00 in HapMap 3, http://hapmap.ncbi.nlm.nih.gov/
) and therefore represent the same genetic signal. Where
studies had data available for both SNPs, we used the SNP
that was genotyped in the largest number of individuals.
Details of genotyping methods within each study are pro-
vided in online supplementary material.
Adiposity measures
Direct physical measurements included weight, height,
waist and hip circumferences, arm circumference,
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triceps skinfold and subscapular skinfold thickness. Fat
mass and fat-free mass were available from bioimpe-
dance measures, while leptin and adiponectin were the
two biochemical markers related to fat mass.
BMI (weight/height2) and waist-hip ratio (waist/hip)
were calculated.
Waist circumference and waist-hip ratio were taken as
key measures of central adiposity, while BMI acted as a
non-speciﬁc measure of adiposity for purposes of adjust-
ment in regression analysis.
Smoking status
Smoking status was self-reported (either by question-
naire or interview) at the same time as regional adiposity
measures for all studies, with the exception of 1958 BC
(see online supplementary material). Individuals were
classiﬁed as current, former, ever (ie, current and
former combined) or never cigarette smokers. Where
information on pipe and cigar smoking was available,
individuals reporting being current or former smokers
of pipes or cigars but not cigarettes were excluded from
all analyses.
For studies with adolescent populations (ALSPAC chil-
dren and NFBC 1986), analyses were restricted to
current daily smokers who reported smoking at least one
cigarette per day (current smokers) and individuals who
had never tried smoking (never-smokers).
Statistical analysis
Analyses were conducted within each contributing study
using Stata (Stata Corp, College Station, Texas, USA)
and R (R Foundation for Statistical Computing, Vienna,
Austria. http://www.R-project.org) software, following
the same analysis plan. Analyses were restricted to indivi-
duals with full data on smoking status and rs1051730/
rs16969968 genotype, and having data on at least one of
the regional adiposity phenotypes.
Within each study, genotype frequencies were tested
for deviation from the Hardy Weinberg Equilibrium
(HWE) using a χ2 test. Mendelian randomisation ana-
lyses of the association between rs1051730/rs16969968
and each regional adiposity phenotype were performed
using linear regression, stratiﬁed by smoking status
(never, former and current) and sex, and adjusted for
age. Apart from height, natural logarithmic transforms
were taken of every anthropometric phenotype. An addi-
tive genetic model was assumed on log values, so that
each effect size could be exponentiated to represent the
percentage increase per minor (risk) allele. These ana-
lyses were presented separately for each smoking status
category. All phenotypic measures were further adjusted
for log(BMI) (apart from weight, height and BMI
itself), thus assessing the effect of the particular adipos-
ity measure after adjusting for this global weight
measure. Log(weight) was adjusted for height instead of
log(BMI). Since adjustment for ratio variables in
anthropometric studies has been criticised,19 we further
adjusted waist circumference for log(weight) and height.
Finally, we repeated analysis of waist circumference
adjusted for BMI restricted to participants with BMI
under 30 kg/m2; 95% CIs have been quoted for all
effect sizes.
Meta-analysis was also carried out of the relationship
between reported daily cigarette consumption and
rs1051730/rs16969968 genotype, among current smokers.
Although analyses were carried out separately for
males and females, the estimates were combined where
no evidence for separate sex effects was seen. For
NHANES, which has a survey design, Taylor series linear-
isation was implemented to estimate variances. For
studies including related family members, appropriate
methods were used to adjust SEs: in GEMINAKAR, twin
pair identity was included as a cluster variable in the
model; in MIDSPAN, linear mixed effects regression
models ﬁtted using restricted maximum likelihood were
used to account for related individuals, while in NTR,
only unrelated individuals were included. ALSPAC
mothers and children were analysed as separate samples;
as there are related individuals across these samples, sen-
sitivity analyses were performed excluding each of these
studies in turn.
Results from individual studies were meta-analysed in
Stata (V.13) using the ‘metan’ command from Stata.
Where there was evidence of heterogeneity between
studies (I2 >50%), it was planned that both ﬁxed and
random effects analyses would be performed: however,
as this never occurred, results for ﬁxed effects analysis
only are shown. Meta-regression analysis, using the
‘metareg’ command from Stata, was used to examine
whether SNP effects varied by smoking status or by sex,
or by a smoking by sex combination.
RESULTS
Descriptive statistics
The maximum sample size available, with genotype
recorded, was 148 731 for weight, height and BMI over
29 studies. The data on individuals with weight, height,
smoking status and genotype recorded included 66 809
never-smokers, 43 009 former smokers and 38 913
current smokers. Waist circumference was available in 28
studies (n=142 381), and hip circumference and waist-
hip ratio in 25 studies (n=139 667). Measures of fat mass
and fat-free mass were provided by 10 studies
(n=28 231), arm circumference by nine studies
(n=72 536), and skinfolds by ﬁve studies (n=7758).
Finally, leptin and adiponectin were measured in nine
studies (n=23 630 and 19 191, respectively). Overall,
47% of the combined study population was male. The
median age within the contributing studies ranged from
16–74 years. Descriptive statistics for each of the study
populations are found in the supplementary material
(see online supplementary table S1).
Minor allele frequency for rs1051730/rs16969968
ranged between 0.31 and 0.36. There was no strong evi-
dence for deviation from the Hardy-Weinberg
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Equilibrium in any of the studies (p values all ≥0.09, see
online supplementary table S2).
Mendelian randomisation analysis
Table 1 shows the per-allele increases in each phenotype
within each smoking status category. As previously
shown,9 the increase in BMI was positive in never-
smokers: +0.35% (95% CI 0.18% to 0.52%;
p=6.38×10−5), non-signiﬁcant in former smokers:
−0.14% (95% CI −0.34% to +0.07%; p=0.19) and signiﬁ-
cantly inverse in current smokers: −0.74% (95% CI
−0.96% to −0.51%; p=2×10−10). The full results for each
contributing study are shown in online supplementary
ﬁgure S1.
The waist circumference was higher per minor allele
in never-smokers: +0.23% (95% CI 0.09% to 0.36%;
p=0.0012), non-signiﬁcantly related in former smokers
−0.07% (95% CI −0.24% to 0.09%; p=0.37) and lower
in current smokers −0.40% (95% CI −0.57 to −0.22
p=1.69×10−5): differences among smoking groups were
highly signiﬁcant (p=3.85×10−7; see online supplemen-
tary ﬁgure S2. The per-allele effect on waist circumfer-
ence in current smokers was about half the magnitude
of that seen for BMI. After adjustment for log(BMI), the
minor allele of rs1051730-rs16969968 was not associated
with waist circumference in either never-smokers:
+0.01% (95% CI −0.06 to 0.08; p=0.72) or former
smokers +0.06% (95% CI −0.02% to 0.15%; p=0.15).
However, in current smokers, the minor allele was asso-
ciated with a 0.14% (95% CI 0.05% to 0.22%; p=0.003)
higher waist circumference after adjustment for log
(BMI). Very similar results were seen in all three
smoking status categories after waist was adjusted for log
(weight) and height instead of for log(BMI). Effects of
genotype on waist circumference were shown to differ
between smoking status categories before adjustment
(p=3.85×10−7) but only weakly after adjustment for log
(BMI) (p=0.102), and after adjustment for log(weight)
and height (p=0.018). Little heterogeneity of study
results was evident (I2≤25% within all smoking groups).
After restricting analysis to participants with BMI under
30 kg/m2, we found that the percentage increases in
waist circumference (after adjustment for log(BMI))
were 0.04% (95% CI −0.03% to 0.12%) for never-
smokers, 0.03% (95% CI −0.06% to 0.13%) for
ex-smokers and 0.12% (95% CI 0.02% to 0.21%) for
current smokers: however, the test for difference in
effects gave p=0.41.
Unadjusted results for hip circumference were very
similar to that seen for waist, both in direction and mag-
nitude, in all smoking status groups (see online supple-
mentary ﬁgure S3). However, after adjustment for log
(BMI), effects were not apparent in any of the three
groups, and nor was the interaction of gene and
smoking status.
Results for the waist-hip ratio were similar to the BMI,
waist and hip circumferences in direction but were
smaller in magnitude: +0.07%, 0.00% and −0.08%
increases in never-smokers, former smokers and
current smokers, respectively (p=0.083 for differences
between smoking categories; see online supplementary
ﬁgure S4). After adjustment for log(BMI), increases
remained non-signiﬁcant for never-smokers and former
smokers (−0.01% and 0.04%) but increased signiﬁcantly
among current smokers (0.10%) (p=0.13 for differences
among smoking groups).
For several other phenotypes, per-allele decreases were
observed in current smokers that exceeded those seen
either in former or never-smokers (see online supple-
mentary table S4). However, there was only statistical evi-
dence for decreases among current smokers for arm
circumference (p=8.4×10−5) and leptin (p=0.025), while
the difference between smoking groups was only signiﬁ-
cant for arm circumference (p=3.29×10−4). Both effects
became non-signiﬁcant after adjustment for log(BMI).
Fat mass and fat-free mass, after adjustment by height,
showed differences in effects by smoking group. These
effects were more due to per-allele increases seen among
never-smokers than decreases among current smokers.
Meta-regression analyses showed no clear evidence for
associations between genotype and each adiposity
phenotype being modiﬁed by sex: p values exceeded 0.1
for all phenotypes, adjusted or unadjusted, apart from
hip circumference. The per-allele decreases in hip cir-
cumference among current smokers appeared more
marked among women (p=0.067), but this effect was no
longer apparent after adjusting for BMI (p=0.51).
The mean difference in daily cigarette consumption
was 0.77 among current smokers (95% CI 0.67 to 0.88,
I2=17%).
DISCUSSION
This meta-analysis of 29 studies comprising almost
150 000 participants with key adiposity phenotypes has
demonstrated, ﬁrst, that a variant associated with
increased cigarette consumption was associated not only
with lower BMI among current smokers, consistent with
earlier ﬁndings,7 8 but also with lower waist and hip cir-
cumferences. Second, the inverse association of the
variant with lower waist circumference among current
smokers changed direction after adjusting for BMI. The
variant was positively associated with waist circumference
but associated neither with hip circumference after BMI
adjustment nor waist-hip ratio. Our results suggest that
for every copy of the minor allele associated with cigar-
ette consumption (ie, increasing cigarette per day con-
sumption by approximately one cigarette), waist
circumference will be increased by 0.14% if BMI were to
remain constant. This suggests a preferential redistribu-
tion towards central adiposity associated with higher cig-
arette consumption: this important ﬁnding is in keeping
with our hypothesis and extends current observational
data.
We also observed that none of the effects were modi-
ﬁed by sex, contrary to our second hypothesis. Finally,
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Table 1 Per allele percentage increases in measures of regional adiposity (BMI, weigh, waist circumference, hip circumference, waist-hip ratio) among never, ex and
current smokers, before and after adjustment for BMI
Adjusted for age Adjusted for age and BMI p For
interaction*BMI (kg/m2) Never-smokers Former smokers Current smokers p For interaction* Never-smokers Former smokers Current smokers
% increase 0.35 −0.14 −0.74 –
95% CI (0.18 to 0.52) (−0.34 to 0.07) (−0.96 to −0.51)
p 6.38×10−5 0.19 2.00×10−10 4.95×10−13
N 66 809 43 009 38 912
I2 14% 0% 0%
Waist circumference (cm)
% increase 0.23 −0.07 −0.40 0.01 0.06 0.14
95% CI (0.09 to 0.36) (−0.24 to 0.09) (−0.57 to −0.22) (−0.06 to 0.08) (−0.02 to 0.15) (0.05 to 0.22)
p 0.0012 0.37 1.69×10−5 3.85×10−7 0.72 0.15 0.003 0.087
N 64 265 40 756 37 360
I2 14% 0% 10% 0% 0% 13%
Hip circumference (cm)
% increase 0.17 −0.07 −0.31 0.02 0.02 0.02
95% CI (0.08 to 0.26) (−0.17 to 0.04) (−0.42 to −0.19) (−0.03 to 0.07) (−0.04 to 0.08) (−0.05 to 0.08)
p 2.95×10−4 0.23 2.55×10−7 1.79×10−9 0.38 0.54 0.59 0.99
N 62 323 40 512 36 833
I2 7% 0% 0% 16% 0% 0%
Waist-hip ratio
% increase 0.07 0 −0.08 −0.01 0.04 0.1
95% CI (−0.01 to 0.15) (−0.10 to 0.10) (−0.19 to 0.03) (−0.08 to 0.06) (−0.04 to 0.13) (0.02 to 0.19)
p 0.087 0.97 0.14 0.083 0.78 0.30 0.02 0.13
N 62 322 40 512 36 833
I2 21% 9% 15% 0% 0% 13%
*Interaction assessed by assessing heterogeneity between effect estimates according to smoking status, with a fixed effects model.
BMI, body mass index.
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we have already noted among never-smokers an unex-
pected positive association of the gene variant with
BMI9: the current analysis demonstrates this same associ-
ation with waist and hip circumferences. This occurred
in the opposite direction to the inverse association of
various adiposity measures with the gene variant seen in
current smokers (before adjustment for BMI).
The analysis consisted of never, former and current
smokers from a very wide spectrum of ages among the
29 studies. The sample size was very large for the
primary phenotypes considered here. Participants were
exclusively of self-reported European ancestry, and were
mostly recruited in European countries. Data for direct
measures of fat, such as fat mass, and the biomarker
leptin were available for only about one-ﬁfth of the parti-
cipants whose weight, height, waist and hip were mea-
sured. Effects according to genotype for these
phenotypes showed broadly similar results for the three
smoking categories to those seen for BMI.
Mendelian randomisation has proved a powerful tool
for eliciting causal associations between phenotypic mea-
sures.20 In the present analysis, Mendel’s laws concerning
random assignment of genotype should produce an
unconfounded comparison between the genotype inﬂu-
encing smoking consumption and the outcomes of inter-
est, namely anthropometric phenotypes. Furthermore,
since this random assignment occurs at the very outset of
life, the associations between genotype and anthropomet-
ric measures cannot be due to reverse causality. If the
genotype only inﬂuences smoking consumption, and not
the initiation of smoking, then the relationship between
genotype and anthropometric outcomes would only be
expected among smokers.
In fact, while the variant was associated with lower
waist and hip circumferences among current smokers, it
was associated with greater waist and hip circumferences
among never-smokers. This suggests that the true effect
among current smokers may be even greater than esti-
mated. When we adjusted waist circumference for BMI,
there was no association with the gene variant among
never-smokers. The relative proportions of ever-smokers
and never-smokers were not clearly associated with geno-
type in the CARTA consortium, as reported elsewhere.9
The reversal of the association between waist circumfer-
ence and allele count from negative to positive among
current smokers after adjustment for BMI may be consist-
ent with alternative explanations. First, heavy smokers
may have less muscle mass; however, no association
between allele count and fat-free mass could be detected
in our analysis among smokers. Second, the test for inter-
action for smoking status and allele count on waist cir-
cumference after adjustment was of weak statistical
signiﬁcance. Third, the adjustment of one measure of
adiposity with another with which it is highly correlated
may have caused a spurious association. We repeated our
analysis for participants with BMI under 30 only, where
the correlation was more modest, and obtained similar
results, albeit with reduced evidence for an effect.
Stratiﬁcation of our analyses by smoking status could,
in theory, introduce bias by conditioning on a collider
(rs1051730/rs16969968).21 This variant shows some evi-
dence for association with smoking cessation (current vs
former smoking).22 While this is a possibility, no effect
modiﬁcations of this variant with potential confounders
by smoking status were demonstrated among 56 625 par-
ticipants in the HUNT study.8
Cross-sectional observational data from Switzerland
has demonstrated that waist and hip circumferences
were more strongly related to the number of cigarettes
smoked per day than was BMI,13 while in Scotland being
a smoker was associated with greater central adiposity
among women.12 In a Finnish longitudinal twin cohort
study, smoking in adolescence predicted abdominal
obesity in adulthood.11 Observational data are, however,
prone to confounding and reverse causality, and the
present study adds some evidence that the associations
reported are likely to be causal.
Some observational studies have noted that low fat-free
mass23 and bone mineral density24 were more common
among smokers. The present analysis has not substan-
tiated the association with fat-free mass, although our
sample size was much more limited for this phenotype.
Our ﬁndings resonate with observational studies which
have shown associations between smoking and risk of
diabetes,17 18 especially as analysis of the British
Women’s Heart and Health Study showed that abdom-
inal adiposity was a stronger predictor of diabetes than
was BMI.16 Waist circumference and waist-to-hip ratio
were strongly associated, independently of BMI, with the
risk of death among 359 387 participants from nine
countries in the European Prospective Investigation into
Cancer and Nutrition.15 Therefore, the health hazards
of smoking could well be enhanced or partly mediated
through increasing abdominal adiposity. In addition, the
desire of many smokers to use smoking as a means of
weight control2 might be counterproductive if a loss of
weight is accompanied by a relative increase in waist cir-
cumference: this possibility could be used in counselling
people seeking to quit smoking.
People who quit smoking appear to be at increased
risk of acquiring diabetes in the short term but this was
not explained by weight gain in a Japanese population.25
This study took place almost exclusively among white
European participants, and replication of the ﬁndings
among other ethnic populations would be of great
value. This is especially urgent on a global scale since
smoking levels are increasing among several non-white
ethnic groups, and this is seen to be partly responsible
for increases in coronary heart disease mortality in
Beijing, China,26 in Syria27 and in Tunisia among
women.28 In addition, increases in average waist circum-
ference have been observed even when average BMI
levels have remained constant,29 and metabolic disor-
ders, especially diabetes, have increased in prevalence.30
It is thus possible that increased CHD mortality will be
partly fuelled by increasing smoking levels.
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Mendelian randomisation studies have more potential
than traditional observational epidemiological studies to
establish causality for speciﬁc exposures,20 and they
should now be used to investigate other impacts of
smoking, in particular on pathways leading to type 2
diabetes, as well as on type 2 diabetes itself. The ﬁnd-
ings of this study could now be further tested by assem-
bling data from randomised trials of smoking cessation,
where postintervention data on measures of central adi-
posity are available. If conﬁrmed, a tendency for
smokers to acquire an ‘apple shape’ due to increasing
central adiposity might provide a novel health promo-
tion message to encourage smoking cessation, and
appropriate new interventions should then be designed
and evaluated as part of overall tobacco control policies
in society.
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